Key result
Thyroxin therapy in subjects with subclinical hypothyroidism decreased carotid intima-media thickness from pre- to post-treatment.
Why the study?
Does thyroxin treatment reduce carotid intima-media thickness in patients with subclinical hypothyroidism?
Meta-Analysis (n=747)
Does thyroxin treatment reduce carotid intima-media thickness in patients with subclinical hypothyroidism?
Thyroxin replacement therapy in patients with subclinical hypothyroidism significantly reduces carotid intima-media thickness and improves lipid profiles, potentially slowing atherosclerosis progression.
Answers are grounded in this paper and cite their sources.
Supports thyroxin in subclinical hypothyroidism to potentially slow atherosclerosis; extends meta-analytic evidence on CIMT as surrogate.
AIM: Research shows that subclinical hypothyroidism (SCH) is related to an increased carotid intima-media thickness (CIMT), a surrogate marker of subclinical cardiovascular disease (CVD). It is controversial whether or not SCH should be treated to reduce CVD morbidity and mortality. This meta-analysis aimed to determine whether SCH is associated with an increase in CIMT as compared to Euthyroidism (EU) and whether thyroxin (T4) treatment in SCH can reverse the change in CIMT. METHODS: Two independent reviewers conducted an extensive database research up to December 2016. A total of 12 clinical trials discussed the effect of Thyroxin on CIMT values at pre- and post-treatment in subjects with SCH. The total cholesterol (TC), triglycerides (TG), and low-density lipoprotein (LDL) were higher in SCH as compared to EU controls and decreased significantly after treatment with thyroxin. CONCLUSION: This meta-analysis shows that thyroxin therapy in subjects with SCH significantly decreases CIMT and improves lipid profile, modifiable CVD risk factors. Thyroid hormone replacement in subjects with SCH may play a role in slowing down or preventing the progression of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Aziz et al. (2017) conducted a meta-analysis in Subclinical Hypothyroidism (SCH) (n=747). Thyroxin vs. Pre-treatment baseline was evaluated on Change in carotid intima-media thickness (CIMT) from pre- to post-treatment (WMD -0.32 mm, 95% CI -0.47, -0.16, p=<0.0001). Thyroxin therapy in subjects with subclinical hypothyroidism decreased carotid intima-media thickness from pre- to post-treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: